Three-Year Changes in Visual Function in the Placebo Group of a Randomized Double-Blind International Multicenter Safety Study: Analysis of Electroretinography, Perimetry, Color Vision, and Visual Acuity in Individuals With Chronic Stable Angina Pectoris

The effect of verapamil 120 mg t.d.s. was compared with propranolol 160 mg b.d. in the treatment of stable angina pectoris. Nineteen patients were studied in a randomized, double-blind, crossover trial, using patient diaries, exercise-testing and ambulatory electrocardiographic monitoring. Both drugs were given for 1 month. On average the number of attacks of angina was reduced equally by verapamil and propranolol. The degree of electrocardiographic evidence of myocardial ischaemia was decreased by the same amount, but verapamil was significantly more effective in prolonging the exercise time. Both drugs reduced the number of episodes of ST-segment depression during 24 hours of ambulatory electrocardiographic monitoring, which was analyzed in nine patients. It is concluded that verapamil compares very favourably with propranolol in the treatment of stable angina, and is more beneficial in improving exercise capacity.

Download Full-text

Dipyridamole in chronic stable angina pectoris. A randomized, double blind, placebo-controlled, parallel group study

European Heart Journal ◽

10.1053/euhj.2001.2623 ◽

2001 ◽

Vol 22 (19) ◽

pp. 1785-1793 ◽

Cited By ~ 23

Author(s):

E Picano, on behalf of the PISA (Pers

Keyword(s):

Angina Pectoris ◽

Stable Angina ◽

Chronic Stable Angina ◽

Stable Angina Pectoris ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group Study ◽

Parallel Group

Download Full-text

Quality Control Procedures and Baseline Values for Electroretinography, Perimetry, Color Vision, and Visual Acuity in an International Multicenter Study: Observations from a Safety Trial in Chronic Stable Angina Pectoris

Translational Vision Science & Technology ◽

10.1167/tvst.9.8.38 ◽

2020 ◽

Vol 9 (8) ◽

pp. 38

Author(s):

Eberhart Zrenner ◽

Graham E. Holder ◽

Ulrich Schiefer ◽

John M. Wild

Keyword(s):

Quality Control ◽

Visual Acuity ◽

Angina Pectoris ◽

Multicenter Study ◽

Chronic Stable Angina ◽

Stable Angina Pectoris ◽

Control Procedures ◽

Baseline Values ◽

International Multicenter Study ◽

International Multicenter

Download Full-text

Acupoint Application in Patients with Chronic Stable Angina Pectoris: Study Protocol of a Randomized, Double-Blind, Controlled Trial

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2014/619706 ◽

2014 ◽

Vol 2014 ◽

pp. 1-8 ◽

Cited By ~ 8

Author(s):

Yulan Ren ◽

Dehua Li ◽

Hui Zheng ◽

Junling Lv ◽

Junyan Leng ◽

...

Keyword(s):

Angina Pectoris ◽

Study Protocol ◽

Stable Angina ◽

Controlled Trial ◽

Chronic Stable Angina ◽

Treatment Phase ◽

Controlled Clinical Trial ◽

Stable Angina Pectoris ◽

Double Blind

Background. Chronic stable angina pectoris (CSAP) is a major syndrome of ischemic heart disease (IHD). CSAP manifests as chest pain or discomfort and affects patients’ quality of life. Acupoint application (AP) has been reported to be effective for managing the symptoms of CSAP, but the evidence is not convincing. Therefore, we designed a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of AP in the treatment of CSAP.Methods and Analysis. Two hundred participants with CSAP will be randomly assigned in a 1 : 1 : 1 : 1 ratio into 4 groups. All participants will receive 12 sessions of treatment in 4 weeks and the same basic treatment procedure. The participants will be visited and assessed for 12 weeks, including a 4-week screening, a 4-week treatment phase, and a 4-week follow-up phase. The primary outcome is the change in the total frequency of self-reported angina attack at 4th week compared with the baseline. The secondary outcomes include the intensity of angina pain, consumption of nitroglycerin orSuxiao Jiuxinpills, CCS angina classification, SAQ, SAS and SDS score.Ethics. The study protocol has been reviewed and approved by the Sichuan Regional Ethics Review Committee on TCM (number 2013kl-001). This trial is registered with clinicaltrials.govNCT02029118.

Download Full-text

A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.

Heart ◽

10.1136/hrt.57.4.336 ◽

1987 ◽

Vol 57 (4) ◽

pp. 336-343 ◽

Cited By ~ 34

Author(s):

I N Findlay ◽

K MacLeod ◽

G Gillen ◽

A T Elliott ◽

T Aitchison ◽

...

Keyword(s):

Angina Pectoris ◽

Stable Angina ◽

Chronic Stable Angina ◽

Stable Angina Pectoris ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Randomized Double-blind Placebo-controlled Comparison of Nicardipine and Nifedipine in Patients with Chronic Stable Angina Pectoris

CHEST Journal ◽

10.1378/chest.89.2.260 ◽

1986 ◽

Vol 89 (2) ◽

pp. 260-265 ◽

Cited By ~ 13

Author(s):

Michael J. Bowles ◽

Nardev S. Khurmi ◽

Martin J. O’Hara ◽

Edward B. Rafiery

Keyword(s):

Angina Pectoris ◽

Stable Angina ◽

Chronic Stable Angina ◽

Stable Angina Pectoris ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial

BMC Complementary and Alternative Medicine ◽

10.1186/s12906-019-2778-z ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Yang Li ◽

Lei Zhang ◽

Shuzheng Lv ◽

Xiaozeng Wang ◽

Jian Zhang ◽

...

Keyword(s):

Clinical Trial ◽

Placebo Group ◽

Angina Pectoris ◽

Randomized Clinical Trial ◽

Stable Angina ◽

Efficacy And Safety ◽

Stable Angina Pectoris ◽

Double Blind ◽

Double Blind Placebo ◽

St Segment

Abstract Background To assess the efficacy and safety of oral Guanxinshutong (GXST) capsules in Chinese patients with stable angina pectoris (SAP) in a prospective, multicenter, double-Blind, placebo-controlled, randomized clinical trial (clinicaltrials.gov Identifier: NCT02280850). Methods Eligible patients were randomized 1:1 to the GXST or placebo group. Current standard antianginal treatment except for nitrate drugs was continued in both groups, who received an additional 4-week treatment of GXST capsule or placebo. Primary endpoint was the change from baseline in angina attack frequency after the 4-week treatment. Secondary endpoints included the reduction of nitroglycerin dose, score of Seatntle Agina Questionnaire, exercise tolerance test defined as time to onset of chest pain and ST-segment depression at least 1 mm greater than the resting one. Results A total of 300 SAP patients from 12 centers in China were enrolled between January 2013 and October 2015, and they were randomly divided into the GXST group and the placebo group (150 patients in each group). Of whom, 287 patients completed the study (143 patients in the GXST group, 144 patients in the placebo group). The baseline characteristics of the two groups were comparable. After 4-week treatment with GXST capsules, the number of angina attacks and the consumption of short-acting nitrates were significantly reduced. In addition, the quality of life of patients were also substantially improved in the GXST group. No significant differences in the time of onset of angina and 1-mm ST segment depression were noted between the two groups. 7 patients (4.1%) in the GXST group and 3 patients (2.1%) in the placebo group reported at least one adverse event, respectively. Conclusions GXST capsules are beneficial for the treatment of SAP patients.

Download Full-text